Core Viewpoint - The CEO of Vison Pharma, Lu Anbang, stated that the Hong Kong Stock Exchange (HKEX) has a higher compatibility with unprofitable innovative drug companies due to its IPO reform initiated in 2018, which has facilitated the listing process for such companies [1] Group 1: Company Insights - Vison Pharma successfully went public in March this year, becoming the "first stock in growth and development" [1] - The company benefits from the international nature of the Hong Kong market, which enhances its visibility [1] Group 2: Industry Perspective - Lu Anbang expressed hope that HKEX will continue to enrich and refine its support policies for innovative enterprises across different industries and development stages [1] - The aim is to create a more vibrant capital market ecosystem for innovative companies [1]
维昇药业执行董事兼CEO卢安邦：港交所与未盈利创新药企业契合度更高